top of page

Cystic Fibrosis Treatment Approved for Use in Children Aged 2 to 5 Years

Officials with the FDA have updated the label of lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals), approving the treatment's use in children aged 2 to 5 years old; with this approval, it is now the first drug to treat the underlying cause of cystic fibrosis (CF) in this population, according to a press release. Lumacaftor/ivacaftor is indicated for the treatment of CF in patients who have 2 copies of the F508del-CFTRmutation, the most common genetic form of the disease. The treatment has already been approved for use in patients aged 6 years and older. This approval is based on data from a phase 3 trial involving 60 patients that showed treatment with lumacaftor/ivacaftor was safe and well tolerated for 24 weeks in this patient population. According to the data, patients demonstrated improvements in sweat chloride, a secondary endpoint, at week 24, as well as changes in key growth parameters. Lumacaftor/ivacaftor demonstrated a safety profile similar to that in patients aged 6 years and older. The most common adverse effect associated with its use was cough and most adverse effects were mild or moderate in severity. In the trial, 4 patients experienced serious adverse events and 3 patients discontinued treatment due to treatment emergent adverse events or elevated liver function tests. Click to continue reading on Specialty Pharmacy Times.

Featured Posts
Recent Posts
Search By Tags
bottom of page